A Pennsylvania Biopharma Therapeutics company (Subsidiary of a Biotech company from China) has appointed Aagami for supporting their out-licensing/co-...
Published : 15 Jul 2021
Read MoreA Swedish biotech company has chosen Aagami to support them for Partnering including Investment, Licensing, Co-development, and other forms for their ...
Published : 11 Jun 2021
Read MoreAagami has been appointed to advise a Mid-West US Pharma for commercial arrangements such as raising investment capital, licensing, and other forms of...
Published : 19 May 2021
Read MoreAagami is pleased to announce that it has forged strategic alliances in China, Europe and UK to have more foots on the ground and provide enhanc...
Published : 15 May 2021
Read MoreA US based company developing Novel Portable Point-Of-Care MRI for Neuro Imaging and Interventions, has appointed Aagami for supporting their need for...
Published : 19 Apr 2021
Read MoreIn August 2020, we announced that an India based large global pharma has signed a term sheet with a Biotech client of Aagami. Now a definitive ag...
Published : 10 Mar 2021
Read MoreA Japanese BioPharma has chosen Aagami to find marketing / sales / distribution partner for their Lidocaine 10% Topical Patch, which is due for U...
Published : 09 Mar 2021
Read MoreAagami has completed 40+ one-on-one strategic meetings at Biotech Showcase which started during JPM week in January. As the meetings are online this t...
Published : 02 Feb 2021
Read MorePlease note that effective November 01, 2020, our office address has reverted to:Aagami Inc.2020 Calamos Court, Suite 200Naperville, Illinois 60563USA...
Published : 03 Nov 2020
Read MoreAagami is appointed by a Clinical stage French Pharma developing a smoking cessation drug extracted from natural tobacco leaf , for support...
Published : 23 Sep 2020
Read More